| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 11
| Issue : 6 | Page : 196-201 |
|
|
Radiotherapy with temozolomide provides better survival in the newly diagnosed glioblastoma multiforme: A meta-analysis
Chonghao Wang1, Na Zhu2, Linshu Wang3, Zhe An4
1 Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, Beijing 100050, China
2 Biotech Center for Viral Disease Emergency, National Institute for Disease Control and Prevention, Chinese Disease Control and Prevention, Beijing 102206, China
3 Department of Clinical Medicine, Harbin Medical University, Harbin 150081, China
4 Department of Cardiology, -Japan Union Hospital of Jilin University, Changchun 130033, China
Correspondence Address:
Zhe An
Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130033
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.168184
|
|
|
Background: The optimal treatment for patients with newly diagnosed glioblastoma multiforme (GBM) remains controversial. The purpose of this meta-analysis was to systematically evaluate radiotherapy/temozolomide (TMZ) versus radiotherapy for treating newly diagnosed GBM.
Materials and Methods: Six electronic databases (PubMed, EMBASE, MEDLINE, Web of Science, Cochrane Library, and CNKI) were searched for relevant publications up to November 05, 2014. RevMan version 5.2 software was used for statistical analysis.
Results: A total of 9 studies were identified in this analyses, which included 986 patients. The summary risk ratio (RR) for overall survival and the progression-free survival (PFS) was the measure of interest. Results revealed that the addition of TMZ to radiotherapy resulted in a statistically significant survival benefit in poor prognosis patients with newly diagnosed glioblastoma (RR = 2.93 [95% confidence interval (CI) 2.29, 3.75], P < 0.00001). Moreover, radiotherapy plus TMZ was more beneficial than radiotherapy alone in improving PFS (RR = 3.52, [95% CI 2.53, 4.89], P < 0.00001). However, certain grade 3–4 hematological toxicities were significantly more common with TMZ.
Conclusions: This meta-analysis suggests that radiotherapy/TMZ provides better survival than radiotherapy alone in treating GBM. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
